Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus.

systemic lupus erythematosus biomarkers prediction B cells plasma cells B lymphocyte belimumab biologics In stratified analysis, differences in relative to baseline B and plasma cell changes between SRI-4 responders and non-responders did not reach statistical significance among patients who received add-on belimumab (any dose or administration route) or among patients who received ST alone ( Figure 1 ).

also in 111,027 other papers